Literature DB >> 24183565

Drug-eluting stent trials: too much non-inferiority, too little progress?

Robert A Byrne1, Adnan Kastrati2.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24183565     DOI： 10.1016/S0140-6736(13)62240-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Overlapping meta-analyses of bioresorbable vascular scaffolds versus everolimus-eluting stents: bringing clarity or confusion?

Authors:  Davide Capodanno
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  Bioresorbable drug eluting scaffolds-are bioresorbable stents ready for today's clinical practice?

Authors:  Christoph Lutter; Michael Joner
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

Review 3.  Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.

Authors:  Scott K Aberegg; Andrew M Hersh; Matthew H Samore
Journal:  J Gen Intern Med       Date:  2017-09-05       Impact factor: 5.128

Review 4.  Endpoint selection for noninferiority percutaneous coronary intervention trials: a methodological description.

Authors:  Matthias Waliszewski; Mark Rosenberg; Harald Rittger; Viktor Breul; Florian Krackhardt
Journal:  Ther Adv Cardiovasc Dis       Date:  2020 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.